Earth Science Tech: An OTC Maverick Plots Its Path to a Major Exchange

AUSTIN, Texas – February 17, 2026 – In a market often dominated by cash-burning startups and speculative ventures, Earth Science Tech Inc. (OTC: ETST) is carving out a distinct identity. The diversified holding company is not only profitable and cash-flow positive but is now publicly signaling its ambition to graduate from the OTC markets to a major national exchange. In a recent interview on the IBN BioMedWire Podcast, Chairman and CEO Giorgio R. Saumat laid out a strategy built on vertical integration, financial discipline, and calculated diversification, positioning ETST as a company for investors to watch closely.

A Vertically Integrated Healthcare Model

At the heart of Earth Science Tech's strategy is a tightly integrated healthcare ecosystem designed to control the patient journey from initial consultation to final fulfillment. This model, as Saumat explained, connects the company's various subsidiaries into a seamless operational flow.

“Earth Science Tech, at this time, is a strategic holding company with core assets in healthcare, mostly compounding pharmaceuticals and online telehealth,” Saumat stated on the podcast. “We are creating a vertically integrated healthcare company. From the marketing side we have Peaks Curative, our online telehealth subsidiary, all the way through Mister Meds and RxCompoundStore.com that fulfill the patient.”

This structure allows ETST to capture value at multiple points. Peaks Curative, a telehealth platform focusing on high-demand areas like weight loss and sexual health, serves as the primary patient acquisition engine. It funnels customers seeking discreet and convenient care to licensed providers who then prescribe custom treatments. These prescriptions are exclusively filled by ETST’s own compounding pharmacies, Mister Meds and RxCompoundStore.com, which are licensed to operate in over 20 states.

The company is operating in two robust sectors. The global telehealth market, while normalizing after its pandemic-era peak, remains a powerful force in healthcare delivery, especially for mental health and specialized treatments. Simultaneously, the U.S. compounding pharmacy market, valued at nearly $5 billion in 2023, is projected to exceed $6.2 billion by 2029. This growth is fueled by a rising demand for personalized medicine, alternative drug formulations, and solutions to frequent drug shortages—a niche ETST’s pharmacies are built to serve. By integrating these services, ETST not only enhances efficiency but also builds a defensible moat in a competitive landscape populated by giants like Teladoc and Walgreens.

The Financial Bedrock for an Uplist

Perhaps the most compelling part of ETST’s story is its financial health, a rarity in the OTC space. Saumat emphasized the company's self-sufficiency and strong fundamentals. “We have not had any need to tap the capital markets in the last three years. The company is strong on a cash flow basis and has a very strong balance sheet,” he noted. “There are not many OTC companies that are cash flow positive with positive EPS and a strong balance sheet as we have. We have very little debt.”

Recent financial disclosures substantiate these claims. For its third fiscal quarter ending December 31, 2025, ETST reported revenues of $8.4 million, a 14.1% year-over-year increase, and a remarkable 341% surge in net income to $910,000. Its gross profit margin improved to a healthy 76.3%, and the company generated $1.2 million in positive cash from operations fiscal year-to-date. With a reported net income of $3.3 million for fiscal year 2025, management is projecting an increase of over 40% for the next fiscal year, bolstered by an anticipated $1.4 million in annualized cost savings.

This financial discipline is the foundation for the company’s next major strategic move: a potential uplisting to a senior exchange like the NASDAQ or NYSE. “We’re preparing the company for a proper uplist, and I think that’s going to help with our liquidity as the market finally gets to know who we are and gets our story out,” Saumat said.

Navigating the Path to a Major Exchange

An uplisting is a significant undertaking that requires more than just financial stability. It involves meeting stringent criteria related to minimum share price, market capitalization, publicly held shares, and, crucially, corporate governance. Companies must adhere to strict SEC regulations and undergo a rigorous review process that can take the better part of a year.

ETST appears to be methodically checking these boxes. The company recently engaged Semple, Marchal & Cooper LLP, a PCAOB-registered accounting firm, as its new independent auditor. This move is a critical step in ensuring its financial statements meet the rigorous standards required by major exchanges. Furthermore, its board includes independent directors, another key governance requirement.

The benefits of a successful uplist are substantial. It would expose Earth Science Tech to a much larger pool of institutional investors, who are often prohibited from investing in OTC-listed securities. This could dramatically increase trading volume and liquidity, provide greater access to capital for future growth, and enhance the company's overall credibility and market profile. While challenges exist, including heightened regulatory scrutiny and the pressure to maintain listing standards, the potential rewards align perfectly with management’s growth ambitions.

Diversification and Scaling for the Future

While healthcare forms its core, ETST's strategy includes a broader vision of a diversified holding company. Its portfolio includes Avenvi, a real estate and asset management arm, and an 80% stake in MagneChef, a direct-to-consumer kitchen products brand. Though less is publicly known about the financial performance of these non-healthcare ventures, they represent a strategic hedge and open additional avenues for growth.

This diversified approach speaks to a long-term vision of building a resilient, multi-faceted enterprise. Saumat alluded to this strategy, stating, “We made some diversification moves in 2025, and I think we’re going to be building on those throughout the rest of 2026.”

This combination of a profitable core business and strategic diversification has put the company in an enviable position. Platforms like the BioMedWire podcast provide a crucial megaphone, allowing emerging companies to bypass traditional gatekeepers and communicate their story directly to the investment community. As ETST works to elevate its profile, this direct line of communication will be invaluable. For now, the company's focus is clear. Having built a nimble and profitable machine, the next chapter is about expansion. As Saumat concluded, “Luckily, we’re small and nimble, so we were able to put it together. Now it’s time to scale it, which is what we’re headed toward.”